Document ID: chunk:federal_register_of_legislation:F2025C00158:clause:4_1:p29
Version: federal_register_of_legislation:F2025C00158
Segment Type: clause
Provision Reference: sch 4 cl 1 (pt 29/381)
Character Range: 11661729–11672957

further PBS-subsidised treatment with this drug for this condition within this treatment cycle.
                                                                                                                                                                    A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.
C10807              P10807         CN10807          Bimekizumab                                                                                                     Severe chronic plaque psoriasis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Compliance with Authority Required procedures
                                                                                                                                                                    Continuing treatment, Whole body or Continuing treatment, Face, hand, foot - balance of supply
                                                    Guselkumab                                                                                                      Patient must have received insufficient therapy with this drug under the continuing treatment, Whole body restriction to complete 24 weeks treatment; or
                                                                                                                                                                    Patient must have received insufficient therapy with this drug under the continuing treatment, Face, hand, foot restriction to complete 24 weeks treatment; AND
                                                    Tildrakizumab                                                                                                   The treatment must be as systemic monotherapy (other than methotrexate); AND
                                                                                                                                                                    The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restrictions; AND
                                                                                                                                                                    Must be treated by a dermatologist.
C10814              P10814         CN10814          Morphine                                                                                                        Chronic severe disabling pain                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Compliance with Authority Required procedures
                                                                                                                                                                    Continuing PBS treatment after 1 June 2020
                                                                                                                                                                    Patient must have previously received PBS-subsidised treatment with this form of this drug for this condition after 1 June 2020.
                                                                                                                                                                    Palliative care nurses may conduct annual review under this item for the treatment of palliative care patients only.
C10830              P10830         CN10830          Apomorphine                                                                                                     Parkinson disease                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Compliance with Authority Required procedures - Streamlined Authority Code 10830
                                                                                                                                                                    Patient must have experienced severely disabling motor fluctuations which have not responded to other therapy; AND
                                                                                                                                                                    The treatment must be commenced in a specialist unit in a hospital setting.
C10836              P10836         CN10836          Morphine                                                                                                        Chronic severe disabling pain                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Compliance with Authority Required procedures
                                                                                                                                                                    The condition must require daily, continuous, long term opioid treatment; AND
                                                                                                                                                                    Patient must have cancer pain.  or
                                                                                                                                                                    Patient must have had or would have inadequate pain management with maximum tolerated doses of non-opioid or other opioid analgesics.  or
                                                                                                                                                                    Patient must be unable to use non-opioid or other opioid analgesics due to contraindications or intolerance.
C10837              P10837         CN10837          Morphine                                                                                                        Cancer pain
                                                                                                                                                                    Continuing PBS treatment after 1 June 2020
                                                                                                                                                                    Patient must have previously received PBS-subsidised treatment with this form of this drug for this condition after 1 June 2020.
                                                                                                                                                                    Palliative care nurses may conduct annual review under this item for the treatment of palliative care patients only.
C10839              P10839         CN10839          Morphine                                                                                                        Severe pain
                                                                                                                                                                    Patient must have had or would have inadequate pain management with maximum tolerated doses of non-opioid and other opioid analgesics.  or
                                                                                                                                                                    Patient must be unable to use non-opioid and other opioid analgesics due to contraindications or intolerance.  or
                                                                                                                                                                    The treatment must be part of pre-operative care.  or
                                                                                                                                                                    The treatment must be